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DIABETES STUDY INVESTIGATORS
OBJECTIVE—Type 2 diabetes is an established risk factor for development of hepatic steatosis
and nonalcoholic fatty liver disease (NAFLD).We aimed to determine the prevalence and clinical
correlates of these conditions in a large cohort of people with type 2 diabetes.
RESEARCH DESIGN ANDMETHODS—A total of 939 participants, aged 61–76 years,
from the Edinburgh Type 2 Diabetes Study (ET2DS)—a large, randomly selected population of
people with type 2 diabetes—underwent liver ultrasonography. Ultrasound gradings of steatosis
were compared with magnetic resonance spectroscopy in a subgroup. NAFLD was deﬁned as
hepatic steatosis in the absence of a secondary cause (screened by questionnaire assessing alcohol
and hepatotoxic medication use, plasma hepatitis serology, autoantibodies and ferritin, and
record linkage to determine prior diagnoses of liver disease). Binary logistic regression was used
to analyze independent associations of characteristics with NAFLD.
RESULTS—Hepatic steatosis was present in 56.9% of participants. After excluding those
with a secondary cause for steatosis, the prevalence of NAFLD in the study population was
42.6%. Independent predictors of NAFLD were BMI, lesser duration of diabetes, HbA1c, tri-
glycerides, and metformin use. These remained unchanged after exclusion of participants with
evidence of hepatic ﬁbrosis from the group with no hepatic steatosis.
CONCLUSIONS—Prevalences of hepatic steatosis and NAFLD were high in this unselected
population of older people with type 2 diabetes, but lower than in studies in which ultrasound
gradings were not compared with a gold standard. Associations with features of the metabolic
syndrome could be used to target screening for this condition.
Diabetes Care 34:1139–1144, 2011
N onalcoholic fatty liver disease(NAFLD), deﬁned as hepatic steatosisin the absence of a secondary cause,
is the commonest cause of liver disease
in westernized countries, affecting up to
33% of the general population (1,2) and
up to 75% in some subgroups such
as obese patients (3). An association
between NAFLD and type 2 diabetes is
well established. Diabetes has been
shown to be a risk factor for the develop-
ment of NAFLD and its progression to
more advanced liver disease including ﬁ-
brosis, cirrhosis, and hepatocellular carci-
noma (4,5). Furthermore, data suggest
that some classes of antidiabetic agents
(6,7) may be used as treatments in
NAFLD.
Despite the recognized association
between type 2 diabetes and NAFLD,
few large-scale studies of the prevalence
of NAFLD in unselected populations of
people with type 2 diabetes are available.
Studies estimating the prevalence using
liver ultrasound have been performed in
secondary care rather than community
setting and have generally examined small
numbers of patients (8). A large study in
Italian outpatients with type 2 diabetes
reported that 85% had hepatic steatosis
and that 70% met the criteria for NAFLD
(deﬁned in that study as hepatic steatosis
without evidence of excess alcohol con-
sumption, viral hepatitis, or causative
medications) (9). This study, however,
was conﬁned to patients attending a hos-
pital clinic and also failed to systemati-
cally identify and exclude participants
with less common causes of liver disease
such as autoimmune hepatitis. Further-
more, ultrasound measurements were
not compared with a gold standard in
the population studied—an important
factor given the variable sensitivity and
speciﬁcity of ultrasound assessment for
hepatic steatosis (10).
Given the rising incidence and prev-
alence of type 2 diabetes, an accurate
estimate of the prevalence of NAFLD, as
well as its clinical correlates, is important
to predict the number of patients whowill
require to be monitored for more ad-
vanced liver disease or who may beneﬁt
from future disease-modifying agents.
The aim of the current study was to
determine the prevalence of NAFLD in a
large, randomly selected population of
older people with type 2 diabetes, using
magnetic resonance spectroscopy (MRS)
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to conﬁrm ultrasound grading classiﬁca-
tions and thorough screening for second-
ary causes of liver disease, and to examine




baseline examination of subjects for the
Edinburgh Type 2 Diabetes Study
(ET2DS) have been described previously
(11). Brieﬂy, subjects recorded as having
type 2 diabetes and aged 60–74 years
were selected at random by sex and 5-
year age bands in years 2006–2007 from
the Lothian Diabetes Register. This is a
comprehensive database of people with
type 2 diabetes living in Lothian, a region
in the south-east of Scotland that includes
the city of Edinburgh and its surrounding
towns and countryside, including both
patients attending a hospital clinic and
those managed solely in primary care.
Study participants (n = 1,066) have been
shown previously to be representative, in
terms of age, HbA1c, duration of diabetes,
insulin treatment, and total cholesterol, of
all those randomly selected to participate
(n = 5,454) and therefore of the target
population of older men and women
with type 2 diabetes living in the gen-
eral population (12). At the time of re-
cruitment into the study, participants
attended a baseline examination that in-
cluded measurement of demographic and
anthropometric variables (age, sex, BMI,
and waist circumference), plasma HbA1c,
total cholesterol, platelets, and hyaluronic
acid. One year after baseline examination,
1,054 participants were invited to attend
a year 1 clinic for assessment of liver
structure and function. A total of 12 par-
ticipants were not invited due to with-
drawal (n = 2), refusal of consent for
contact (n = 5), unsuitable for contact
(n = 3), or death (n = 2). A total of 939
subjects (88% of the original cohort) par-
ticipated in the year 1 clinic. Of those sub-
jects invited but who did not attend the
year 1 clinics (n = 114), 19 were uncon-
tactable, 61 unable or unwilling to attend,
21 repeatedly cancelled or failed to attend
appointments, and 13 had died.
The ET2DSwas approved by the local
research ethics committee, and all partic-
ipants gave written informed consent for
baseline and year 1 examinations.
Ultrasound examination and
comparison with MRS
Subjects attended the year 1 research
clinic after a 4-h fast for an ultrasound
examination of abdomen. All ultrasound
examinations were performed by a single
ultrasonographer, who was unaware of
the clinical and laboratory results of the
participants, using a Sonoline Elegra Ul-
trasound Imaging System (Siemens Med-
ical Systems, Issaquah, WA), software
version 6, with a 3.5-MHz transducer.
The liver was graded for markers of he-
patic steatosis using established criteria
(13–15) including a bright hepatic echo
pattern (compared with the echo re-
sponse of the right kidney), increased at-
tenuation of the echo beam, and the
presence of focal fatty sparing. Partici-
pants were given an overall liver grading
based on a subjective measurement of the
severity of steatosis: grade 0, normal ap-
pearance of liver on ultrasound and ini-
tially graded as a “normal ultrasound”;
grade 1, possible slight increase in echo-
genicity or slightly impaired visualization
of the diaphragm or intrahepatic vessels,
or difﬁculty in grading as a result of a dis-
eased or absent right kidney—initially
termed an “indeterminate ultrasound”;
grade 2, deﬁnite increase in echogenicity
and/or deﬁnite impaired visualization of
the intrahepatic vessels and diaphragm,
no or little evidence of focal fatty sparing,
initially graded as “evidence ofmild steatosis
on ultrasound”; grade 3, marked increase
in echogenicity and/or poor or no visu-
alization of the diaphragm and intrahe-
patic vessels, with or without focal fatty
sparing, initially graded as “evidence of
severe steatosis on ultrasound.” Evidence
of hepatic cirrhosis was also sought sys-
tematically.
Comparison of the ultrasound grad-
ings for hepatic steatosis with 1H MRS,
the noninvasive gold standard for quanti-
ﬁcation of hepatic fat, in a subgroup of 58
participants has previously been de-
scribed in detail (16). In brief, 17 partic-
ipants with a grade 0 ultrasound grading,
19 with grade 1 or 2, and 22 with grade 3
underwent MRS. A grade 0 grading on
ultrasound was associated with a “nor-
mal” hepatic fat fraction on MRS of
,6.1% (17,18) in 14 of 17 cases (and a
fat fraction of ,9% [19,20] in all cases)
and was accepted as “no steatosis.” A
grading of grade 3 on ultrasound was
associated with and MRS hepatic fat
fraction $6.1% in all cases, and this was
therefore taken as “deﬁnite steatosis.” The
group with grade 1 or 2 on ultrasound
had an MRS fat fraction of ,6.1% in 13
of 19 cases, and a fat fraction of , 9%
in 16 of 19 cases, thus displaying consid-
erable overlap with those regarded as
normal. In view of this, the group with
grade 1 or 2 on ultrasound scan was con-
sidered to have a “probable normal” scan.
If a liver FF of$6.1% onMRSwas used to
denote hepatic steatosis, sensitivity, spec-
iﬁcity, and positive and negative predic-
tive values (adjusted for the portion of the
whole study cohort receiving each grad-
ing) of ultrasound in detecting “deﬁnite
steatosis” were 86.8%, 100%, 100%,
and 80.0%, respectively.
Clinical examination
Average alcohol intake per week over the
previous year, a history of alcohol excess,
and use of hepatotoxic medications
within the previous 6 months were de-
termined by questionnaire. Average alco-
hol intake was determined using two
questions adapted from the AUDIT-C
screening tool (21): “How often did you
have a drink containing alcohol in the
past year? Consider a “drink” to be a can
or a bottle of beer, a glass of wine, or one
cocktail or a measure of spirits (like
scotch, gin, or vodka)” (a drink was con-
sidered to be the equivalent of one unit of
alcohol); and “How many drinks did you
have on a typical day when you were
drinking in the last year?”
Those participants with evidence of
hepatic steatosis or abnormal blood tests
of liver function had further investiga-
tions performed including serology for
hepatitis B and C, antinuclear antibody
(ANA), antismooth muscle antibody, an-
timitochondrial antibody, and ferritin. All
participants had brachial blood pressure,
serum triglycerides, and HDL cholesterol
measured.
Information on previous diagnoses of
chronic liver disease was collected from
participants by questionnaire at year 1
and supplemented using data on liver
diagnoses, which had been obtained at
baseline via record linkage to hospital
discharges at the Information and Services
Division (ISD) of NHS Scotland.
Deﬁnition of NAFLD
NAFLD was deﬁned as the presence of
deﬁnite hepatic steatosis on ultrasound
scan (i.e., grade 3) in the absence of a
secondary cause for hepatic steatosis.
Secondary causes were deﬁned as alcohol
consumption $14 units/week (22) or
participant report of current/previous al-
cohol excess; use of hepatotoxic medica-
tion (2) (glucocorticoids, isoniazid,
methotrexate, amiodarone, and tamoxi-
fen) within the 6 months prior to the
year 1 clinic; positive hepatitis B or C
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serology; ferritin concentration $1,000
mg/L (milder hyperferritinemia can be as-
sociated with obesity, insulin resistance,
and NAFLD [2,23]); clinically signiﬁcant
positive immunology titers (antismooth
muscle antibody titer$1:160 [24] or an-
timitochondrial antibody titer $1:40
[25]); or a previous diagnosis of a persis-
tent secondary cause for chronic liver dis-
ease. Subjects were considered to have a
previous diagnosis of a secondary cause
for chronic liver disease if ISD linkage re-
vealed such a diagnosis, or if a participant
report of a diagnosis was conﬁrmed by
their medical records. Subjects were ex-
cluded from calculations on the preva-
lence of NAFLD if data on the above
measures were missing such that a sec-
ondary cause could not be excluded.
Deﬁnition of metabolic syndrome
As per Adult Treatment Panel III criteria,
subjects were considered to have the
metabolic syndrome if, in addition to
type 2 diabetes, they had at least two of
the following: blood pressure$130/85 or
on antihypertensive treatment; triglycer-
ides $1.7 mmol/L or taking a ﬁbrate;
HDL cholesterol ,1.04 mmol/L (men) or
1.29 mmol/L (women); waist circumfer-
ence.102 cm (men) or 88 cm (women).
Statistical analysis
Analysis was performed using SPSS soft-
ware version 14.0. Data that did not
conform to the normal distribution (du-
ration of diabetes and triglycerides) were
log-transformed prior to parametric anal-
ysis. Statistical analysis included the in-
dependent t test and x2 tests to compare
characteristics between groups. Binary lo-
gistic regression analysis was used to as-
sess the independence of variables in their
association with hepatic steatosis and
NAFLD. Variables included in this model
were age, sex, BMI, duration of diabetes,
HbA1c, systolic blood pressure, HDL and
LDL cholesterol, triglycerides, and the use
of metformin, sulfonylureas, thiazolidine-
diones, incretinmimetics, and insulin. Al-
cohol use $14 units/week or previous
alcohol misuse was used as a categorical
variable in the model examining hepatic
steatosis, but not that examining NAFLD.
Results were reported as estimated odds
ratios (ORs) and 95% CI.
RESULTS
Subject characteristics
The characteristics of 939 participants
(aged 61–76 years) attending the year 1
clinic are shown in Table 1. Baseline char-
acteristics of subjects attending the year 1
clinical examination were similar to those
of the total ET2DS population suggesting
that the study population attending for
liver assessment remained representative
of the target general population with type
2 diabetes.
Prevalence of hepatic steatosis
and NAFLD
Of the 939 subjects undergoing abdom-
inal ultrasound, data on steatosis grading
was incomplete for 2 subjects, and these
were excluded from the analysis. Hepatic
steatosis was graded as deﬁnite (grade 3)
on ultrasound examination in 56.9% (n =
533) of the remaining participants. The
appearance of the liver was normal (grade
0) in 23.5% (n = 220) of participants.
Twenty-two subjects (2.3%) were graded
as grade 1 (in three of these cases, it was
commented that the liver was difﬁcult to
scan as it was located high up under the
costal margin) and a further 16.9% (n =
158) were graded as grade 2, giving a total
of 180 subjects (19.2%) who were classi-
ﬁed as “probable normal.” In addition,
0.4% subjects (n = 4) had a liver in which
ultrasound identiﬁed cirrhosis—steatosis
gradings in these subjects were grade 0 in
two participants, grade 1 in one partici-
pant, and grade 2 in one participant.
Among those with evidence of deﬁ-
nite hepatic steatosis (grade 3), 123 sub-
jects had evidence of one or more
secondary causes for steatosis: 78 had
alcohol intake $14 units/week or a his-
tory of excess; 40 had used a hepatotoxic
medication, as outlined above, in the
previous 6months; 1 each had serological
evidence of hepatitis B and C; 3 had ferritin
levels $1,000 mg/L; 1 had antismooth
muscle antibody titer $1:160; 1 had
antimitochondrial antibody titer $1:40;
and 7 had previously diagnosed liver
disease (2 had alcoholic liver disease, 1
hemochromatosis, 1 autoimmune hepa-
titis, 1 recurrent cholangitis, 1 biliary
cirrhosis, and 1 hepatic carcinoid metas-
tases). In a further 19 subjects data were
missing such that a secondary cause
could not be excluded. In addition, a
further 160 participants had at least
one positive immunology titer $1:40,
which was not considered signiﬁcant.
Of these, most had borderline ANA
or antismooth muscle titers (#1:80; n =
120); 40 participants had ANA titer
$1:160.
Using the predeﬁned criteria, 391 out
of 918 participants with a full dataset had
deﬁnite hepatic steatosis on ultrasound
grading with no secondary cause, giving a
prevalence of NAFLD of 42.6% in this
study population.
Table 1—Characteristics of subjects at year 1 clinic
Characteristic Year 1
n 939
Age (years) 68.9 6 4.2
Sex, % (n) male 52.0 (488)
Race, % (n) Caucasian 98.3 (923)
BMI measured at baseline clinic (kg/m2) 31.3 6 5.7
Waist circumference measured at baseline clinic (cm) 106.7 6 12.8
Duration of diabetes (years) 9.0 6 6.4
HbA1c (%) 7.19 6 1.06
Diet controlled, % (n) 19.4 (182)
Oral antidiabetic agent users, % (n) 74.4 (699)
Insulin users, % (n) 15.8 (148)
Systolic blood pressure (mmHg) 138.1 6 18.5
Diastolic blood pressure (mmHg) 74.1 6 9.6
Total cholesterol (mmol/L) 4.15 6 0.81
HDL cholesterol (mmol/L) 1.23 6 0.34
LDL cholesterol (mmol/L) 2.17 6 0.68
Triglyceride (mmol/L) 1.66 6 0.90
Statin users, % (n) 81.6 (767)
Aspirin users, % (n) 67.7 (636)
ACE inhibitor users, % (n) 52.0 (488)
Current or ex-smokers, % (n) 60.0 (563)
Data are mean 6 SD or proportions in whole cohort of participants unless otherwise indicated.





Physical and biochemical characteristics
of study participants according to steatosis
groups are shown in Table 2. In univariate
analysis, participants in the group with
deﬁnite steatosis (grade 3) were signiﬁ-
cantly younger and had lesser duration
of diabetes than the combined normal/
probably normal groups (grades 0, 1,
and 2) (P , 0.05). BMI, waist circumfer-
ence, HbA1c, diastolic blood pressure, tri-
glycerides, and prevalence of alcohol
intake over 14 units/week were signiﬁ-
cantly higher, and HDL cholesterol signif-
icantly lower, in the deﬁnite steatosis
group. Metformin use was more common
in the deﬁnite steatosis group. No signif-
icant differences in the use of other
antidiabetic agents (sulfonylureas, glita-
zones, incretin mimetics, or insulin)
were found.
In multivariate analysis, independent
predictors of deﬁnite hepatic steatosis
(compared with those classed as normal/
probable normal) on ultrasound scan
were BMI (OR 1.07 [95% CI 1.04–
1.10]), lesser duration of diabetes (OR
for log duration diabetes 0.53 [0.30–
0.92]), HbA1c (OR 1.35 [1.15–1.59]), tri-
glycerides (OR for log triglycerides 20.76
[0.85–50.85]), alcohol intake $14 units/
week (OR 3.13 [1.80–5.43]), and use of
metformin (OR 2.19 [1.59–3.00]).
Similar results were obtained when
those with secondary causes for liver
disease were excluded from analysis.
Independent predictors of NAFLD were
BMI (OR 1.07 [95% CI 1.03–1.10]),
lesser duration of diabetes (OR for log
duration diabetes 0.46 [0.25–0.83]),
HbA1c (OR 1.29 [1.08–1.54]), triglycerides
(OR for log triglycerides 17.57 [6.68–
46.18]), and use of metformin (OR 2.25
[1.60–3.17]).
Of the 400 participants who had
gradings of normal/probable normal liver
parenchyma on ultrasound scan, 74 had
at least one of the following features
suggestive of possible hepatic ﬁbrosis or
cirrhosis: spleen size $13 cm (16 partic-
ipants); hyaluronic acid .75 ng/mL (the
upper end of normal on the laboratory
reference range) in the absence of joint
disease (54 participants); or platelet count
,150 3 109/L (20 participants). If these
participants were excluded from regres-
sion analysis, independent predictors of
deﬁnite steatosis and NAFLD were un-
changed (data not shown).
CONCLUSIONS—This is the ﬁrst
study to examine the prevalence of he-
patic steatosis and NAFLD in a popula-
tion of people with type 2 diabetes using
an ultrasound classiﬁcation that has been
reﬁned by comparisonwithMRS andwith
detailed exclusion of secondary causes of
steatosis. The study population included
the full clinical spectrum of type 2 diabetes
and included people who were being
managed in the community as well as in
hospital clinics.
Previous studies have estimated that
a hepatic fat fraction on MRS of under
6.1–9% is consistent with a normal liver,
whereas hepatic steatosis is associated
with higher fat fractions (17–20). Com-
parison of our ultrasound gradings with
MRS suggested that the “deﬁnite steato-
sis” grading was an excellent predictor for
the presence of hepatic steatosis (16). In
contrast, considerable overlap was ob-
served between those graded initially as
having “indeterminate” or “mild” steatosis
(grade 1 or 2) and the normal group, and
it was considered that these participants
probably had a normal liver. Our preva-
lence of hepatic steatosis, at 56.9%, was
therefore considerably lower than in pre-
vious studies including that of a large Ital-
ian population of patients with type 2
diabetes, in which 85.3% were consid-
ered to have hepatic steatosis (9). In
view of these ﬁndings, caution should
be used with regard to the prevalences
reported by previous studies that have
used ultrasound measurements that
have been less rigorously corroborated
for a diagnosis of hepatic steatosis.
NAFLD was the most common cause
for steatosis, accounting for 76% of all
cases. In comparison with previous stud-
ies, our analysis had the advantage of a
more systematic identiﬁcation and exclu-
sion of secondary causes of liver disease in
those with steatosis, both by the use of
ISD linkage to identify previously diag-
nosed chronic liver disease and by the
routine measurement of autoantibody











Age (years) 69.4 6 4.2 68.5 6 4.8 69.5 6 4.4 68.5 6 4.0*
Sex, % (n) male 59.9 (132) 40.9 (9) 49.4 (78) 50.1 (267)
BMI measured at baseline clinic (kg/m2) 28.8 6 5.18 35.1 6 8.4 30.7 6 4.9 32.4 6 5.5*
Waist circumference (cm) 102.4 6 13.5 112.6 6 18.7 104.7 6 11.6 108.9 6 12.0*
Duration of diabetes (years) 9.6 6 7.6 10.5 6 6.0 9.8 6 6.5 8.4 6 5.8*
HbA1c (%) 7.02 6 0.97 7.15 6 0.93 6.99 6 0.98 7.33 6 1.12*
Systolic blood pressure (mmHg) 140.1 6 21.5 141.2 6 22.4 135.9 6 18.6 137.9 6 16.7
Diastolic blood pressure (mmHg) 73.4 6 9.5 76.3 6 11.2 72.1 6 9.5 74.9 6 9.4*
Total cholesterol (mmol/L) 4.14 6 0.81 4.53 6 0.81 4.01 6 0.75 4.17 6 0.82
HDL cholesterol (mmol/L) 1.28 6 0.69 1.16 6 0.27 1.30 6 0.35 1.19 6 0.32*
LDL cholesterol (mmol/L) 2.24 6 0.70 2.57 6 0.72 2.08 6 0.65 2.14 6 0.67
Triglyceride (mmol/L) 1.37 6 0.69 1.76 6 0.67 1.37 6 0.63 1.86 6 1.00*
Metabolic syndrome, % (n) present 70.2 (153) 86.4 (19) 78.3 (123) 91.2 (485)*
Alcohol intake, % (n) over 14 units/week 6.4 (14) 0.0 (0) 7.6 (12) 12.9 (69)*
Metformin use, % (n) 48.2 (106) 50.0 (11) 63.3 (100) 70.9 (378)*
Data are mean 6 SD unless otherwise indicated. *Signiﬁcant difference grade 3 vs. grade 0/1/2 by t test or x2 test, P , 0.05.
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titers and ferritin in all participants with
steatosis. The use of these additional
measures within the group with steatosis
identiﬁed four patients with likely
hemochromatosis, two with likely auto-
immune hepatitis, two with primary
biliary cirrhosis, one with recurrent
cholangitis, and one with hepatic carci-
noid metastases; these accounted for
1.9% of this group. The systemic iden-
tiﬁcation and exclusion of subjects with
any possible secondary cause of steatosis
from the diagnosis of NAFLD may have
caused an underestimation of the prev-
alence of NAFLD, which may in some
cases have been a coexistent pathology.
It is recognized that the cutoffs used to
deﬁne exclusions to the diagnosis of
NAFLD are, to some extent, arbitrary
and the prevalence will depend upon the
precise deﬁnition used.
The majority of exclusions from the
diagnosis of NAFLD were on the basis of
excess alcohol intake. It is recognized that
estimation of alcohol consumption can be
unreliable, and in particular that subjects
and investigators may underestimate in-
take. This, in turn, can lead to overesti-
mation of the prevalence of NAFLD. The
prevalence of alcohol intake $14 units/
week as a secondary cause for steatosis
was relatively low in our study population
(14.6%) when compared with a similar
age band in the general population of
England, in which the prevalence of alco-
hol intake $21 units/week for men and
$14 units/week for women has been
quoted as 23% and 10%, respectively
(26). While this may represent an under-
estimation of intake, it is also possible that
it reﬂects genuinely lower alcohol con-
sumption in a frailer population in which
use of multiple prescription medications
is not uncommon.
Subjects in this study were all aged
61–76 years at the time of examination
and were predominantly Caucasian. Pre-
vious studies have shown that the preva-
lence of NAFLD increases with age
(although we did not ﬁnd evidence of
that within our age range), and therefore
it is possible that the prevalence of
NAFLD in our study population was
greater than that of the general diabetic
population. The results may be less appli-
cable to populations in other countries,
particularly those in which the prevalence
of other causes of liver disease (such as
alcoholic liver disease and viral hepatitis)
is markedly different to that in the U.K.
It has previously been shown that
NAFLD is associated with features of the
metabolic syndrome within the general
population, and the same was true in this
population of people with type 2 diabetes.
The association of a shorter duration of
diabetes with liver disease has been de-
scribed before. One possible explanation
is that the greater degree of hyperinsuli-
nemia in early type 2 diabetes drives
uptake of free fatty acids by hepatocytes.
Unexpectedly, the use of metformin was
associated with the presence of NAFLD,
independently of BMI and glycemic con-
trol. Previous studies of the use of met-
formin in NAFLD have shown a positive
or neutral effect in individuals (6), and it
therefore seems unlikely that there is a
causative link between metformin use
and NAFLD here. It is possible that those
participants who were on metformin had
other risk factors for NAFLD that were not
accounted for in the present analysis,
such as inﬂammatory markers. Further-
more, it is possible that results were con-
founded by indication, i.e., participants
may have been previously prescribed
metformin in an attempt to treat hepatic
steatosis. Finally, it is possible that the
signiﬁcant association between metfor-
min and steatosis was a consequence
of a type 1 statistical error.
It is acknowledged that while data on
most variables were gathered concomi-
tantly with hepatic ultrasound examina-
tion, BMI was calculated 1 year previously
during the baseline examination. It is
therefore possible that the results of the
regression analysis are less robust than
they would have been with fully contem-
poraneous data collection. However,
changes in BMI over 1 year would in
most cases have been small and randomly
distributed throughout the study popu-
lation, and this should not have substan-
tially affected the results of analysis.
Another limitation of this study is that
subjects did not have a liver biopsy and
histological examination, the gold stan-
dard technique for identifying steatosis;
performance of this invasive procedure
would have been neither feasible nor
ethical in a population study of this
magnitude. It was recognized that some
participants with a normal ultrasound
scan could have undiagnosed hepatic
ﬁbrosis and thus be at the severe end of
the spectrum of NAFLD. Of note, any
misclassiﬁed cases would tend to under-
estimate the prevalence of NAFLD and
reduce rather than magnify any differ-
ences in clinical associations between
groups. Furthermore, reanalysis exclud-
ing those participants with a normal liver
ultrasound scan but other evidence of
possible ﬁbrosis revealed similar results to
the main analysis. A further limitation is
that only approximately one-ﬁfth of
patients invited to attend the baseline
clinic from the Lothian Diabetes Register
did so. Signiﬁcantly, however, analysis
revealed that this population was repre-
sentative of that invited in terms of dura-
tion of diabetes, HbA1c, and treatment
with insulin.
In conclusion, in assessing the prev-
alence of NAFLD in people with type 2
diabetes, this study has advantages of
robust ultrasound gradings, systematic
exclusion of other causes for liver disease,
and a relatively large, unselected popula-
tion of older individuals. In the future, it
is possible that the association of liver
disease with other features of the meta-
bolic syndrome could be used to target
screening for NAFLD. Further research is
required to ascertain whether the risk of
progression of NAFLD to cirrhosis in
patients with type 2 diabetes in the clinical
setting is as high as that predicted—if so,
this would provide further impetus to-
ward early diagnosis so that they might
be eligible for entry into clinical trials,
screening for complications, and ultimately
new therapies.
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